Prosecution Insights
Last updated: November 11, 2026
Application No. 18/035,509

TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION

Final Rejection §102§103§112
Filed
May 04, 2023
Priority
Nov 24, 2021 — nonprovisional of PCTUS2021060872
Examiner
GANESAN, SUBA
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Tau Medical Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
506 granted / 686 resolved
+3.8% vs TC avg
Moderate +13% lift
Without
With
+13.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
26 currently pending
Career history
720
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
49.7%
+9.7% vs TC avg
§102
22.4%
-17.6% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 686 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments with respect to claims 12-18 have been considered but are moot in view of the new grounds for rejection. New claims 21-28 are addressed below. Allowable Subject Matter Claims 14-15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: the closest prior art is Kim et al. (Pub. No.: US 2020/0229916), however, Kim fails to fairly teach or suggest a distal tail with variable flexibility. Claim Objections Claim 12 is objected to because of the following informalities: “the the” is a typographical error. Appropriate correction is required. Claim 22 is objected to because of the following informalities: claim 22 depends from cancelled claim 19. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 17-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 17 recites the limitation "the intravascular anchor" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 12-13, 17-18, 21-24, 26-28 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kim et al. (Pub. No.: US 2020/0229916). Kim et al. (hereinafter, Kim) discloses a12. (currently amended) A transcatheter device (e.g., fig. 1) comprising: a main shaft 20 comprising a proximal segment (e.g., fig. 1, near end 60) and a spacer body segment extending from the proximal segment (e.g., fig. 1 under blocking part 10); a distal tail (e.g., near end 30) continuing distally from the main shaft; a spacer body 10 mounted on the the spacer body segment (e.g., fig. 1), wherein the distal tail and the spacer body segment collectively form an overall C-shaped configuration configured (e.g., fig. 1), when implanted, to embrace an anatomical path from the pulmonary artery, across a supraventricular crest of a right ventricle, across a tricuspid valve. through a right atrium, and toward an inferior vena cava (fig. 12). For claim 13, Kim discloses the transcatheter device of claim 12, wherein the spacer body is coaxially mounted around the spacer body segment (e.g., fig. 1, para. 72). For claim 17, Kim discloses the transcatheter device of claim 12, wherein the intravascular anchor 60 is attached to the proximal segment (e.g., fig. 1). For claim 18, Kim discloses the transcatheter device of claim 17, wherein the intravascular anchor is a spiral coil that has at least two spirals (e.g., fig. 6). For claim 21, Kim discloses the transcatheter device of claim 12, wherein the pulmonary artery is a right pulmonary artery (e.g., fig. 12). For claim 22, Kim discloses the transcatheter device of claim 19, wherein the curved shape of the distal tail is configured to position a distal portion of the spacer body closer to the supraventricular crest (e.g., fig. 12). For claim 23, Kim discloses the transcatheter device of claim 12, wherein the distal tail comprises a pigtail tip or a rounded tip configured to reduce trauma as the distal tail travels into the pulmonary artery (e.g., fig. 6). For claim 24, Kim discloses the transcatheter device of claim 12, wherein the distal tail is configured to be advanced over a guidewire 50 into the pulmonary artery and to function as an anchor within the pulmonary artery (e.g., fig. 12). For claim 26, Kim discloses the transcatheter device of claim 12, wherein the distal tail is configured to anchor within a pulmonary artery trunk without extending past a first branching artery of the pulmonary artery (e.g., fig. 12). For claim 27, Kim discloses the transcatheter device of claim 12, wherein the distal tail extends distally from the spacer body segment and has a curved shape configured to partially encircle a pulmonary artery to function as an atraumatic anchor (e.g., fig. 6, 12). For claim 28, Kim discloses the transcatheter device of claim 12, wherein the proximal segment comprises a single bend (e.g., fig. 1). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 16, 25 are rejected under 35 U.S.C. 103 as being unpatentable over Kim et al. (Pub. No.: US 2020/0229916) in view of Gelfand et al. (Pub. No.: US 2006/0064059). For claim 16, Kim does not specify the distal tail has a length of 10 cm to 40 cm. Gelfand et al. (hereinafter, Gelfand) teaches a treatment catheter intervention placed through the vena cava 109, tricuspid valve 102, and pulmonary artery 105, with a length from occlusive balloon 106 to PA balloon 107 of 20-30 cm. Selection of a distal tail length of 10-40 cm would have been an obvious length selection given the implantation area of the distal tail from the tricuspid valve to the pulmonary artery is approximately half the Gelfand length (see Gelfand fig. 1). Therefore selection of a distal tail length of 10-40 cm would have occurred using known methods and would have yielded predictable results. For claim 25, Kim does not specify a distal tail configured to extend into a pulmonary artery main trunk and past at least one pulmonary artery branch, however, a distal tail length of 10-40cm is considered capable of this function. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUBA GANESAN whose telephone number is (571)272-3243. The examiner can normally be reached Monday-Friday, 8 AM - 5 PM Mountain Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUBA GANESAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

May 04, 2023
Application Filed
Feb 18, 2026
Non-Final Rejection mailed — §102, §103, §112
Jun 09, 2026
Response Filed
Sep 30, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758383
ARTICULATED PROSTHESIS FOR A TRICUSPID OR MITRAL VALVE
3y 5m to grant Granted Oct 13, 2026
Patent 12751820
DIAMETRIC EXPANSION FEATURES FOR PROSTHETIC VALVES
2y 8m to grant Granted Oct 06, 2026
Patent 12746115
APPARATUS AND METHODS FOR REDUCING PARAVALVULAR LEAKAGE
3y 5m to grant Granted Sep 29, 2026
Patent 12740862
Medical Device using Bioabsorbable Material
2y 10m to grant Granted Sep 22, 2026
Patent 12721725
PROSTHETIC HEART VALVE HAVING NON-LINEAR STRUTS
4y 3m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
87%
With Interview (+13.4%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 686 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month